Literature DB >> 30552893

Choroidal Microvascular Dropout in Primary Angle Closure Glaucoma.

Harsha L Rao1, Shruthi Sreenivasaiah2, Mohammed Riyazuddin3, Srilakshmi Dasari3, Shivani Dixit2, Jayasree P Venugopal2, Zia S Pradhan2, Narendra K Puttaiah4, Sathi Devi2, Robert N Weinreb5, Kaweh Mansouri6, Carroll A B Webers7.   

Abstract

PURPOSE: To determine the prevalence and factors associated with the presence of choroidal microvascular dropout (CMvD) in primary angle-closure glaucoma (PACG) eyes compared to primary open-angle glaucoma (POAG) eyes.
DESIGN: Cross-sectional study.
METHODS: Thirty-six POAG eyes (36 patients) and 28 PACG eyes (28 patients) underwent optical coherence tomography angiography (OCTA). Presence of CMvD was evaluated on choroidal OCTA slabs. Visual field (VF) defects in the glaucoma eyes were classified into initial nasal defect (IND), initial parafoveal scotoma (IPFS), and combined nasal and parafoveal defect, and the association between type of VF defect and CMvD was evaluated.
RESULTS: CMvD was detected in 21 POAG (58.3%) and 10 PACG (35.7%) eyes (P = .07). CMvD in POAG eyes was associated with pretreatment intraocular pressure (odds ratio [OR] = 0.91/mm Hg higher intraocular pressure, P = .06), VF mean deviation (MD, OR = 0.75/dB higher MD, P = .007), retinal nerve fiber layer thickness (OR = 0.92/μm increase in thickness, P = .02), and peripapillary vessel density (OR = 0.80/unit increase in density, P = .01). CMvD in PACG eyes was associated only with VF MD (OR = 0.90/dB higher MD, P = .05). When analyzed in the entire cohort of glaucoma patients (64 eyes), CMvD was significantly associated with POAG (OR > 3.5, P < .05) after accounting for glaucoma severity. CMvD was seen in 6 of 7 eyes with IPFS and 1 of 13 with IND in the POAG group (P < .05) and 1 of 2 eyes with IPFS and 0 of 10 with IND in the PACG group (P < .05).
CONCLUSIONS: Prevalence of CMvD was significantly lower in PACG compared to POAG. As in POAG, CMvD in PACG was associated with advanced VF damage and with IPFS on VF.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30552893     DOI: 10.1016/j.ajo.2018.11.021

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  The Topographic Relationship Between Choroidal Microvascular Dropout and Glaucomatous Damage in Primary Angle-Closure Glaucoma.

Authors:  Li Tan; Di Ma; Junren He; Hongxi Wang; Shirong Chen; Yongdong Lin
Journal:  Transl Vis Sci Technol       Date:  2022-10-03       Impact factor: 3.048

2.  Determinants of vessel defects in superficial and deep vascular layers in normal-tension glaucoma using optical coherence tomography angiography.

Authors:  Jiyun Lee; Chan Kee Park; Hae-Young Lopilly Park
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

Review 3.  Optical Coherence Tomography Angiography in Glaucoma.

Authors:  Harsha L Rao; Zia S Pradhan; Min Hee Suh; Sasan Moghimi; Kaweh Mansouri; Robert N Weinreb
Journal:  J Glaucoma       Date:  2020-04       Impact factor: 2.290

4.  Choroidal Microvascular Dropout in Pseudoexfoliation Glaucoma.

Authors:  Zia S Pradhan; Harsha L Rao; Shivani Dixit; Shruthi Sreenivasaiah; Praveena G Reddy; Jayasree P Venugopal; Narendra K Puttaiah; Sathi Devi; Robert N Weinreb; Kaweh Mansouri; Carroll A B Webers
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

Review 5.  The characteristics of fundus microvascular alterations in the course of glaucoma: a narrative review.

Authors:  Xintong Fan; Yue Ying; Ruyi Zhai; Qilian Sheng; Yanan Sun; Huan Xu; Xiangmei Kong
Journal:  Ann Transl Med       Date:  2022-05

6.  Macular vessel density and foveal avascular zone parameters in patients after acute primary angle closure determined by OCT angiography.

Authors:  Kangcheng Liu; Huizhuo Xu; Haibo Jiang; Hua Wang; Pingbao Wang; Yi Xu; Fangling Li; Bei Xu; Xueyan Yao; Jing Zou
Journal:  Sci Rep       Date:  2020-10-30       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.